Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tenaya Therapeutics Inc (TNYA)

Tenaya Therapeutics Inc (TNYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 144,326
  • Shares Outstanding, K 216,999
  • Annual Sales, $ 0 K
  • Annual Income, $ -90,600 K
  • EBIT $ -93 M
  • EBITDA $ -84 M
  • 60-Month Beta 3.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.23
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.62
  • Most Recent Earnings $-0.12 on 03/11/26
  • Next Earnings Date 05/06/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 253.32% (+60.84%)
  • Historical Volatility 120.26%
  • IV Percentile 49%
  • IV Rank 20.90%
  • IV High 862.56% on 11/20/25
  • IV Low 92.32% on 01/14/26
  • Expected Move (DTE 18) 0.2125 (31.95%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 97
  • Volume Avg (30-Day) 1,060
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 28,925
  • Open Int (30-Day) 30,155
  • Expected Range 0.4526 to 0.8776

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.09
  • Number of Estimates 5
  • High Estimate -0.06
  • Low Estimate -0.14
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +62.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5316 +25.11%
on 03/03/26
1.0350 -35.74%
on 03/09/26
+0.1033 (+18.39%)
since 02/27/26
3-Month
0.5316 +25.11%
on 03/03/26
1.0350 -35.74%
on 03/09/26
-0.0890 (-11.80%)
since 12/26/25
52-Week
0.3600 +84.75%
on 05/13/25
2.3500 -71.70%
on 10/10/25
-0.0267 (-3.86%)
since 03/27/25

Most Recent Stories

More News
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports...

TNYA : 0.6651 (-5.11%)
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy

Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy  New Data Confirm...

TNYA : 0.6651 (-5.11%)
Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics

Agreement Combines Tenaya’s Expertise in Identification and Validation of Genetic Heart Disease Targets with Alnylam’s Ability to Deliver Transformational Therapeutics Tenaya to Receive Up to...

TNYA : 0.6651 (-5.11%)
ALNY : 317.36 (-3.29%)
Tenaya Therapeutics to Participate in the Leerink Partners Global Healthcare Conference 2026

SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...

TNYA : 0.6651 (-5.11%)
Tenaya Therapeutics Announces 2026 Strategic Priorities and Anticipated Milestones

Aims to Build on Positive 2025 Interim TN-201 Results in First Half of 2026 with  Longer-Term Follow-Up Data for Cohorts 1 and 2 from MyPEAK™-1 Trial of Adults with MYBPC3-Associated HCM Expects...

TNYA : 0.6651 (-5.11%)
Tenaya Therapeutics Announces Pricing of Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...

TNYA : 0.6651 (-5.11%)
Tenaya Therapeutics Announces Proposed Public Offering

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...

TNYA : 0.6651 (-5.11%)
Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

TN-401 was Well Tolerated at 3E13 vg/kg dose  Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients at Week 8 Clinically Meaningful Reductions in Arrhythmia...

TNYA : 0.6651 (-5.11%)
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially...

TNYA : 0.6651 (-5.11%)
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients Initial TN-201...

TNYA : 0.6651 (-5.11%)

Business Summary

Tenaya Therapeutics Inc. is a biotechnology company. It discovers, develop and deliver curative therapies which address the underlying causes of heart disease. The company's product platform consist Gene Therapy, Cellular Regeneration and Precision Medicine. Tenaya Therapeutics Inc. is based in SOUTH...

See More

Key Turning Points

3rd Resistance Point 0.7274
2nd Resistance Point 0.7137
1st Resistance Point 0.6894
Last Price 0.6651
1st Support Level 0.6514
2nd Support Level 0.6377
3rd Support Level 0.6134

See More

52-Week High 2.3500
Fibonacci 61.8% 1.5898
Fibonacci 50% 1.3550
Fibonacci 38.2% 1.1202
Last Price 0.6651
52-Week Low 0.3600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.